Bayer and Meiogenix join forces to advance agricultural research and development

Bayer and Meiogenix, a biotech company focused on next-generation breeding technologies, announced today a collaboration to advance agricultural research and development by accelerating the development of Meiogenix's proprietary technologies related to plant breeding and genome editing applications. This new research collaboration has the potential to deliver much-needed plant health and nutrition improvements to food crops so farmers can more efficiently and sustainably grow improved plant varieties that deliver the types of foods consumers want.

Bayer and Meiogenix join forces to advance agricultural research and development
Plants Genetic Diversity

Farmers need innovative solutions as they face limited natural resources and a changing climate. Access to Meiogenix's proprietary technologies could improve the precision and speed with which our breeders enhance crops, which could ultimately accelerate those solutions for the diverse needs of people and our planet."

Jeremy Williams, Head of Plant Biotechnology, Crop Science Research & Development (R&D) at Bayer

Meiogenix's proprietary technologies are used to induce the exchange of genomic regions between chromosomes of plant cells during meiosis, the natural process that generates genetic diversity during plant breeding. Technologies based on meiotic recombination provide commercial crops with access to a broader genetic diversity, including complex traits for improved food quality, plants' resistance to diseases and pests, and higher yield potential. The resulting hybrids and varieties have the potential to deliver value throughout the food chain, from farmers to consumers.

Over the past decade, we have assembled unique know-how, intellectual property portfolio and network of experts to help generate biodiversity and accelerate breeding through modulating meiotic recombination. We are proud to collaborate with Bayer to develop the next generations of crops."

Giacomo Bastianelli, Co-founder & CEO of Meiogenix

Agriculture is facing the challenge of adjusting plant physiology to rapid climate, pest and disease changes, as well as preparing the next generation of healthier food. Collaborating on these new breeding technologies will be key to bringing innovative solutions to farmers and consumers."

Luc Mathis, strategic advisor of Meiogenix

As part of the project, Meiogenix will collaborate with top academic institutes to advance these technologies in crops.

Bayer offers a wide range of educational materials regarding plant breeding and gene editing technologies on its website.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bayer AG. (2020, February 10). Bayer and Meiogenix join forces to advance agricultural research and development. News-Medical. Retrieved on November 07, 2024 from https://www.news-medical.net/news/20200210/Bayer-and-Meiogenix-join-forces-to-advance-agricultural-research-and-development.aspx.

  • MLA

    Bayer AG. "Bayer and Meiogenix join forces to advance agricultural research and development". News-Medical. 07 November 2024. <https://www.news-medical.net/news/20200210/Bayer-and-Meiogenix-join-forces-to-advance-agricultural-research-and-development.aspx>.

  • Chicago

    Bayer AG. "Bayer and Meiogenix join forces to advance agricultural research and development". News-Medical. https://www.news-medical.net/news/20200210/Bayer-and-Meiogenix-join-forces-to-advance-agricultural-research-and-development.aspx. (accessed November 07, 2024).

  • Harvard

    Bayer AG. 2020. Bayer and Meiogenix join forces to advance agricultural research and development. News-Medical, viewed 07 November 2024, https://www.news-medical.net/news/20200210/Bayer-and-Meiogenix-join-forces-to-advance-agricultural-research-and-development.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.